What Simbec-Orion does

Simbec-Orion is a privately-held full-service Contract Research Organization (CRO) founded in 1976 and headquartered in Merthyr Tydfil, United Kingdom, operating across more than eleven office locations globally, including the UK, France, Germany, Hungary, Netherlands, Poland, Australia, and the United States. The company delivers clinical trial management services for small to mid-size biotech and pharmaceutical drug developers, with a particular therapeutic focus on oncology (including rare oncology), rare and orphan diseases, respiratory therapeutics, CNS indications, and addiction research. Its named customers include KalVista Pharmaceuticals, Oxford Cannabinoid Technologies, Mission Therapeutics, Molecure, AL-S Pharma, ImmuPharma, Exvastat, and Cardiff University, with the client base spread across Europe, the United States, Canada, Australia, New Zealand, and Asia-Pacific.

The company's service portfolio spans the full clinical development lifecycle: early-stage consultancy, First-in-Human and Phase Ib/2a studies, Phase II and Phase III trials, pharmacovigilance, regulatory affairs, medical writing, bioanalytical and central laboratory services, SMO services, and post-market studies. Core infrastructure is anchored by an MHRA-accredited 58-bed Phase I Clinical Pharmacology Unit in Merthyr Tydfil with onsite pharmacy and central laboratory, complemented by an in-house gamma scintigraphy camera operated via a 25-year collaboration with Cardiff Scintigraphics, and bioanalytical capability including Ella ELISA analyzers from ProteinSimple. Technology infrastructure combines proprietary and partner platforms: ClinSpark EDC (launched December 2024) purpose-built for Phase I, and Veeva Vault systems (CTMS, eTMF, and Quality Suite) for trial and quality management. AI capability is delivered through the biotx.ai strategic partnership for causal modeling aimed at de-risking Phase II efficacy predictions.

Simbec-Orion operates as a professional services business on custom project-based contracts to biotech and pharma customers; pricing is not publicly disclosed. The legal structure is Simbec-Orion Group Limited with wholly-owned operating subsidiaries across multiple jurisdictions (Simbec Research Ltd, Orion Clinical Services Ltd, Orion Clinical Services Inc, Orion Santé Sarl, Simbec-Orion (NL) B.V., Orion Clinical Services Hungary Kft, Orion Clinical Services GmbH, Simbec-Orion (POL) sp. z o.o, and Orion Clinical Services (Australia) Pty Limited). Distribution is direct via enterprise field sales, with operational reach extended to 34 countries through the February 2025 Avance Clinical partnership. Marketing is conducted through educational content (white papers, webinars, case studies, clinical trial publications), industry conference participation (BIO International, ASCO, World Orphan Drug Congress, BioWales), and LinkedIn, with the company recognized as 2019 European Lifestars "CRO of the Year."

Name

Simbec-Orion

Legal name

Simbec-Orion Group Limited

Website

https://simbecorion.com

Company type

Private

Founded year

1976

Operating status

Operating

Headcount range

251–500 employees

Short description

Simbec-Orion is a UK-based, privately-held full-service Contract Research Organization delivering clinical trial management services from First-in-Human through Phase III, with specialty focus on oncology and rare diseases. The company serves small and mid-size biotech and pharmaceutical developers globally across 34 countries through direct enterprise sales and an MHRA-accredited Phase I unit.

Ownership category

akta.pro rank

Product category

Clinical Research Services (Contract Research Organization)

NAICS

Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)

Keywords

• Clinical trial management
• Contract research organization
• Early phase clinical studies
• Central laboratory services
• Regulatory affairs consulting

Headquarters

HQ city

Merthyr Tydfil

HQ country

United Kingdom

HQ region

Europe

Offices11 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Clinical Trial Management Services: Full-service clinical development solutions covering Phase I through Phase III and post-market studies. Services include clinical trial management, biometrics, site management and monitoring, and IMP management
2. Clinical Pharmacology Services: Purpose-built clinical pharmacology unit conducting all types of studies including First-in-Human, PK, food effect, drug-drug interaction studies. 90% of work with Investigational Medicinal Products
3. Central Laboratory Services: Bioanalytical laboratory services, routine safety testing, immunoassays with on-site capabilities for rapid turnaround of sample analysis including safety analysis, biomarkers, and drug concentration analysis
4. Regulatory Affairs: Regulatory affairs consulting and submission services including ethics and CTA submissions
5. Clinical & Medical Writing: Medical and clinical writing services for study documentation and regulatory submissions
6. Scintigraphy Services: Specialized gamma scintigraphy imaging services for respiratory therapeutics research, conducted in partnership with Cardiff Scintigraphics
7. Pharmacovigilance: Drug safety monitoring and pharmacovigilance services
8. SMO Services: Site Management Organization services for site-level clinical trial support

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Simbec-Orion is a full-service Contract Research Organisation (CRO) that manages clinical trials end-to-end for small and mid-sized biotech and pharmaceutical sponsors, covering Phase I (including First-in-Human, PK, food effect, and drug-drug interaction studies) through Phase III and post-market studies from its MHRA-accredited 58-bed Phase I Clinical Pharmacology Unit. It sells complementary services including central laboratory/bioanalytical testing, scintigraphy imaging, pharmacovigilance, regulatory affairs and submissions, clinical and medical writing, biometric services, site management and monitoring, IMP management, and SMO services, with deep specialization in oncology, rare and orphan diseases, respiratory, and CNS therapeutic areas.

Product overview

Simbec-Orion is a full-service Contract Research Organisation (CRO) offering a comprehensive portfolio of clinical development solutions from early phase (Phase I) through Phase III and post-market studies. The company operates as a single unified platform combining clinical trial management, laboratory services, clinical pharmacology, regulatory affairs, and specialized therapeutic expertise. Key service modules include Clinical Trial Management Services (encompassing Phase I, II, III, site management, IMP management, and biometrics), Central Laboratory Services (bioanalytical, routine safety testing, immunoassays), Clinical Pharmacology, Scintigraphy, Pharmacovigilance, Regulatory Affairs, and Clinical & Medical Writing. The company specializes in oncology and rare disease therapeutic areas, complemented by AI-powered causal modeling capabilities through its biotx.ai partnership. Technology infrastructure includes ClinSpark® electronic data capture platform and Veeva Vault systems (CTMS, eTMF, Quality Suite).

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Management Services Full-service clinical trial management covering Phase I through Phase III and post-market studies, including site management and monitoring, IMP management, and biometric services. Targeted at biotech and pharmaceutical sponsors.
• Central Laboratory Services Comprehensive laboratory support including bioanalytical services, routine safety testing, and immunoassays for clinical sample analysis. Includes an on-site bioanalytical laboratory for safety, biomarker, and drug concentration analysis. Targeted at clinical trial sponsors.
• Clinical Pharmacology Full-service clinical pharmacology unit conducting First-in-Human studies, Phase Ib/2a proof of concept, PK/food effect/drug-drug interaction studies, and patient cohort trials at an MHRA-accredited facility with 58-bed capacity. Targeted at biotech and pharmaceutical sponsors needing early-phase development support.
• Scintigraphy Services Gamma scintigraphy imaging services for respiratory therapeutics research, using an in-house gamma scintigraphy camera with over 25 years of experience in scintigraphy trials. Provided in partnership with Cardiff Scintigraphics. Targeted at respiratory drug developers.
• Pharmacovigilance Drug safety monitoring and pharmacovigilance services provided throughout the clinical trial process. Targeted at biotech and pharmaceutical sponsors requiring continuous safety oversight.
• Regulatory Affairs Regulatory strategy and submission services including ethics and Clinical Trial Application (CTA) submissions, leveraging early regulatory engagement through Scientific Advice. Targeted at biotech and pharmaceutical sponsors needing regulatory pathway support.
• Clinical & Medical Writing Professional medical and clinical writing services for study documentation and regulatory submissions. Targeted at biotech and pharmaceutical sponsors.
• Data Quality, Security & Compliance Data management services ensuring quality, security, and regulatory compliance for clinical trial data, integrated with Veeva Vault CTMS and eTMF. Targeted at clinical trial sponsors needing end-to-end data oversight.
• SMO Services Site Management Organization services providing site coordination, management, and monitoring support for clinical trial sites. Targeted at biotech and pharmaceutical sponsors needing site-level execution support.
• Early Stage Consultancy Services Early-stage drug development advisory and consultancy services including Scientific Advice consultation. Delivered with support from an independent Drug Development Advisory Board including former MHRA experts. Targeted at biotech and pharmaceutical sponsors planning early development programs.
• AI Causal Modeling Service AI-enabled causal modeling service through the biotx.ai partnership that processes nonclinical data to predict Phase II efficacy and identify comprehensive biomarker endpoints for clinical development. Targeted at biotech and pharmaceutical sponsors seeking to de-risk early-stage drug development.
• ClinSpark® Electronic Data Capture Platform State-of-the-art electronic data capture (EDC) platform purpose-built to optimize Phase I studies, integrated into Simbec-Orion's clinical technology stack. Targeted at clinical trial sponsors running Phase I trials.

Quantifiable outcome

• Delivered Phase II results for KVD900 demonstrating statistically and clinically significant responses across all endpoints
• +2 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability3 records

Feature7 records

Partnerships

14 partnerships are on record, tiered core and minor.

• Avance ClinicalcoreStrategic or Co-development Partner · 26 February 2025Strategic partnership agreement forming collaborative framework between two full-service CROs to deliver globally integrated clinical trial solutions. Partnership enables Simbec-Orion to expand into Australia and Asia-Pacific while extending Avance Clinical's capabilities in Europe and UK. Combined operations span 34 countries across Europe, US, Canada, Australia, New Zealand, and Asia. Both CROs operate as unified entity to execute Phase I through Phase III trials.
• biotx.aicoreTechnology or Integration · 26 October 2023Strategic partnership to bring AI-powered insights and predictive models to support data-driven clinical trial design. biotx.ai provides AI-enabled causal modeling for drug development that is closer to human systems than traditional animal models, offering more accurate predictions for efficacy in Phase II. Partnership helps de-risk early-stage drug development.
• Veeva SystemscoreTechnology or IntegrationPartnership for Veeva Vault clinical applications including Vault CTMS and Vault eTMF for end-to-end clinical trial data and document management, and Veeva Vault Quality Suite for quality management. Alison Hughes recognized as Veeva Hero for implementation leadership. Systems enable digital execution and quality oversight.
• ImmuPharmacoreStrategic or Co-development PartnerPartnership for international Phase III trial of Lupuzor, an in-development treatment for Lupus affecting approximately 5 million people worldwide. Trial involves pharmacokinetic studies following FDA approval.
• Oxford Cannabinoid TechnologiescoreStrategic or Co-development PartnerTrusted to conduct milestone first-in-human Phase I clinical trial of lead compound OCT461201 for Postherpetic Neuralgia (PHN) and Irritable Bowel Syndrome. Represents significant milestone for Oxford Cannabinoid's clinical development program.
• MolecurecoreStrategic or Co-development PartnerAgreement signed July 2023 to conduct Phase II clinical trial for Molecure's lead molecule OATD-01 in pulmonary sarcoidosis patients, taking important step in development program.
• Mission TherapeuticscoreStrategic or Co-development PartnerSuccessful delivery of Phase I clinical trial for MTX652 (lead DUB program), achieving milestone showing drug was well tolerated and safe up to single dose of 200mg and multiple doses of 100mg once daily for 14 days.
• AL-S PharmacoreStrategic or Co-development PartnerSupporting Phase II ALS Study (AP-101) in Amyotrophic Lateral Sclerosis, a rare progressive neurodegenerative disease. AP-101 is monoclonal antibody administered by intravenous infusion targeting misfolded SOD1.
• KalVista PharmaceuticalscoreStrategic or Co-development PartnerPhase II clinical trial for KVD900 as oral on-demand treatment for Hereditary Angioedema attacks, demonstrating statistically and clinically significant responses across all endpoints with reduced rescue medication use.
• ExvastatminorStrategic or Co-development PartnerCollaboration on COVID-19 trial studying imatinib in treatment of COVID-19 associated ARDS. Exvastat won 3.6 million euro grant from Innovative Medicines Initiative for reformulation and study.
• Cardiff ScintigraphicscoreStrategic or Co-development PartnerOver 25-year collaboration with Cardiff Scintigraphics for scintigraphy trials on asthmatic and COPD patients using in-house gamma scintigraphy camera.
• The Science BehindminorStrategic or Co-development PartnerPartnership for EEG assessments in Phase I unit for schizophrenia cognitive impairment trial, combining neuroscience, neurology and psychology expertise with electro-diagnostic technology.
• Cardiff University Brain Research Imaging Centre (CUBRIC)minorStrategic or Co-development PartnerNeuroimaging conducted at CUBRIC for Phase I trial with Cardiff University's Medicines Discovery Institute, supporting South Wales drug development network.
• Oncodistinct NetworkcoreStrategic or Co-development PartnerCharter agreement strengthening relationships between Simbec-Orion and Oncodistinct network of oncology sites for partnership in operations and scientific expertise in design and conduct of early phase oncology studies.

Scale indicators6 records

Recent moves12 records

Expansion highlights7 records

Direct peers

• Medpace Holdings: Public mid-size CRO (NASDAQ: MEDP) renowned for its biotech-focused operating model and lean scientific staffing. Closest publicly traded analog and benchmark on unit economics for a biotech-focused CRO of Simbec-Orion's profile.
• Worldwide Clinical Trials: Mid-size, full-service CRO with comparable therapeutic specialization (rare disease, oncology, CNS) and similar biotech/mid-pharma customer mix. Operates as a private mid-tier alternative to mega-CROs, directly contesting Simbec-Orion for the same Phase II/III contracts.
• Premier Research: Mid-size full-service CRO historically focused on small/mid-size biotech with strong rare disease, oncology, and pediatric credentials. Highly comparable on therapeutic focus, customer segment, and project-based clinical delivery model.
• Clinipace Worldwide: Private mid-size CRO with therapeutic breadth across oncology, rare disease, and infectious disease, serving small-to-mid biotech. Direct competitor for the same Phase II-III RFPs and similar clinical technology stack.
• Avance Clinical: Australia-headquartered full-service mid-size CRO that signed a strategic partnership with Simbec-Orion in February 2025 to deliver unified Phase I-IV services across 34 countries. Most directly comparable peer given similar size, biotech focus, and formalized cross-region alliance.

Broad incumbents

• IQVIA: Global CRO/pharma services leader with comprehensive Phase I-IV capabilities. Simbec-Orion competes for the small/mid-biotech subset of contracts where customers seek a more agile partner than the mega-CROs.
• Charles River Laboratories: Large preclinical/clinical services provider; its Discovery & Safety Assessment segment plus early-phase clinical franchise directly competes with Simbec-Orion's Phase I unit and central lab services for biotech accounts.
• INC Research (Syneos Health legacy): Large global CRO formed from the merger of INC Research and inVentiv; provides end-to-end clinical services that overlap Simbec-Orion's offerings but at greater scale and broader therapeutic coverage, including late-phase and post-marketing.
• ICON plc: Top-tier global CRO offering Phase I-IV and post-approval services. Overlaps with Simbec-Orion's biotech/biopharma customer segment but at much larger scale and broader geographic footprint.

Others

• ERT (Clario): Clinical trial technology and endpoint services provider; relevant comparator because Simbec-Orion's ClinSpark EDC, Veeva Vault integration, and Ella ELISA platform mix clinical services with technology tooling in similar fashion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/simbecorion
• Xx.com/simbecorion

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Simbec-Orion